Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
23 studies found for:    "Indolent B cell lymphoma"
Show Display Options
RSS Create an RSS feed from your search for:
"Indolent B cell lymphoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Sofosbuvir+Ledipasvir ±Ribavirin and Sofosbuvir+Ribavirin for Pts With Indolent Bcell Lymphoma Associated With HCV Infection Treatment With Sofosbuvir Plus Ledipasvir ± Ribavirin(G1, 3 and 4) and Sofosbuvir+Ribavirin(G2) for Pts With Hepatitis C Virus Associated Indolent B-cell Lymphomas
Conditions: Indolent B-cell Lymphoma;   Hepatitis C
Interventions: Drug: Sofosbuvir+Ledipasvir;   Drug: Sofosbuvir+Ribavirin;   Drug: Sofosbuvir+Ledipasvir+Ribavirin
2 Active, not recruiting High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas
Conditions: B-cell Lymphoma;   Indolent B-cell Lymphoma
Intervention: Drug: rituximab
3 Recruiting Indolent Non Follicular Lymphomas Prognostic Project
Condition: Indolent B-Cell Lymphomas
Intervention: Other: Any treatment, watch and wait policy included
4 Not yet recruiting p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
Conditions: T-cell Lymphoma;   Aggressive B-cell Lymphoma;   Non-Hodgkin's Lymphomas;   Indolent B-cell Lymphoma
Interventions: Drug: Decitabine;   Drug: Tetrahydrouridine
5 Recruiting A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
Conditions: Indolent B-cell Lymphoma;   Chronic Lymphocytic Leukaemia;   Waldenström Macroglobulinaemia
Intervention: Drug: DI-B4
6 Active, not recruiting Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Small Lymphocytic Lymphoma
Intervention: Drug: ofatumumab
7 Recruiting Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma
Condition: Lymphoma
Intervention: Radiation: Radiation Therapy
8 Recruiting Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: PI3K inhibitor BKM120;   Biological: rituximab;   Other: Pharmacodynamics;   Other: Correlative studies
9 Completed VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Conditions: B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Lymphoma
Intervention: Drug: VELCADE and rituximab
10 Withdrawn Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, B-Cell, Marginal Zone;   Lymphoma, Low-Grade;   Lymphoma, Intermediate-Grade
Intervention: Drug: Ofatumumab
11 Not yet recruiting Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Conditions: B Cell Lymphoma;   Lymphoma
Interventions: Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Rituximab
12 Completed
Has Results
Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology
Conditions: Lymphoma, Non-Hodgkin;   Non-Hodgkin's Lymphoma
Intervention: Biological: tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)
13 Active, not recruiting Bortezomib and Romidepsin in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Indolent B-cell Lymphoma, Peripheral T-cell Lymphoma or Cutaneous T-Cell Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Bortezomib;   Drug: Romidepsin
14 Recruiting Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Condition: Leukemia
Interventions: Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide
15 Terminated A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma, B-Cell
Intervention: Drug: AEG35156 antisense IV infusion
16 Unknown  Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine;   Biological: autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine;   Biological: autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine
17 Not yet recruiting Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Small-Cell;   Waldenstrom Macroglobulinemia;   Lymphoma, B-Cell, Marginal Zone
Interventions: Drug: Rituximab;   Drug: Bendamustine;   Drug: Vincristine sulfate liposome injection
18 Completed Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma
Intervention: Drug: bortezomib + rituximab
19 Unknown  Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine;   Biological: rituximab;   Biological: sargramostim
20 Completed Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: keyhole limpet hemocyanin;   Biological: sargramostim;   Biological: tumor cell-based vaccine therapy

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Indicates status has not been verified in more than two years